Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Longeveron (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call Investor Brand Network - Fri May 3, 9:01AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase Investor Brand Network - Mon Apr 29, 9:28AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2,...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) Closes on Warrant Exercise Offering, Public Offering Investor Brand Network - Mon Apr 22, 10:22AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M Investor Brand Network - Thu Apr 18, 9:30AM CDT

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M Investor Brand Network - Mon Apr 15, 9:01AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering Investor Brand Network - Wed Apr 10, 8:37AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) Discusses 2023 Progress, 2024 Plans in Corporate Update Investor Brand Network - Mon Apr 1, 9:36AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split Investor Brand Network - Thu Mar 21, 9:03AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock....

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results Investor Brand Network - Thu Feb 29, 9:39AM CST

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report...

LGVN : 1.4550 (-5.52%)
Longeveron (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results Investor Brand Network - Fri Feb 23, 2:14PM CST

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The...

LGVN : 1.4550 (-5.52%)

Barchart Exclusives

1 Overlooked AI Stock for Growth and Passive Income Barchart - Fri May 10, 2:15PM CDT
This overlooked tech company posted strong results and guidance leading to an upgrade from analysts. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot